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Introduction: Tight glycemic control (TGC) has shown benefits but been difficult to achieve 
consistently. STAR (Stochastic TARgeted) is a flexible, model-based TGC approach that directly 
accounts for intra- and inter- patient variability with a stochastically derived maximum 5% risk of 
blood glucose (BG) below 72mg/dL.  
 
Objectives: To assess the safety, efficacy and clinical burden of a STAR TGC controller 
modulating both insulin and nutrition inputs in pilot trials. 
 
Method: Seven patients covering 660 hours. Insulin and nutrition interventions are given 1-3 
hourly as chosen by the nurse to allow them to manage workload. Interventions are designed to 
maximize the overlap of the model-predicted (5-95
th
 percentile) range of BG outcomes with the 
4.0-6.5mmol/L band, and thus guarantee a maximum 5% risk of BG<4.0mmol/L..   
 
All measurements were taken with bedside glucometers. Interventions are calculated using 
clinically validated computer models of human metabolism and its variability in critical illness. 
Carbohydrate intake (all sources) was selected to maximize intake up to 100% of SCCM/ACCP 
goal (25kg/kcal/hour). Insulin doses were limited (8U/hour maximum), with limited increases 
based on current rate (0.5-2.0U/hour). 
 
For context, BG results are compared to those for the SPRINT TGC cohort at the same hospital 
(current standard of care), which reduced mortality 25-40% for LoS≥3days. 
 
Written informed consent was obtained for all patients, approval was granted by the NZ Upper 
South A Regional Ethics Committee. 
 
Results: 402 measurements were taken over 660 hours (1.65 hourly or 14.5/day), as nurses 
showed a preference for 2-hourly measurements (<10 3 hours intervals chosen). Median [IQR] 
cohort BG was 5.9 [5.2-6.8]mmol/L. Overall, 63.2%, 75.9% and 89.8% of measurements were in 
the 4.0-6.5mmol/L, 4.0-7.0mmol/L and 4.0-8.0mmol/L bands. There were no hypoglycemic events 
(BG<2.2mmol/L) and the minimum recorded BG was 3.5mmol/L with 4.5% <4.0mmol/L. Only 
0.2% (1 measurement) exceeded 10.0mmol/L. 
 
Per-Patient the median [IQR] hours of TGC was 92 [29-113]hours using 53 [19-62] 
measurements (median: ~13.5 measurements/day). Median [IQR] per-patient results were: BG, 
5.9 [5.8-6.3]mmol/L; Carbohydrate Administered, 6.8 [5.5-8.7]g/hour (~70% goal feed median 
using low CHO enteral nutrition); Insulin Administered, 2.5 [0.1-5.1]U/hour. All patients achieved 
BG<6.1mmol/L. 
 
For comparison, the SPRINT cohort BG was 5.7 [5.0-6.6]mmol/L, and per-patient median BG was 
5.8 [5.3-6.4]mmol/L, with a 2% (by patient) rate of hypoglycemia. 
 
Conclusion: STAR TGC modulating insulin and nutrition inputs provided very tight control with 
minimal variability by managing intra- and inter- patient variability. Performance and safety 
exceed that of SPRINT, which reduced mortality and cost in the Christchurch ICU. The use of 
glucometers did not appear to impact the quality of TGC. Finally, clinical workload was self-
managed and reduced 20% compared to SPRINT. 
